000			03216na a2200397 4500
999			_c3221 _d3221
003			PC3221
005			20210625062759.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aVera, Francisco _92433 _eCirugía Cardiovascular
245	0	0	_aSafety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. _h[artículo]
260			_bHIV clinical trials, _c2013
300			_a14(5):204-15.
500			_aFormato Vancouver: Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P et al. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. HIV Clin Trials. 2013 Sep-Oct;14(5):204-15.
501			_aPMID: 24144897
504			_aContiene 43 referencias
520			_aOBJECTIVES: Current antiretroviral guidelines state that being older than 50 to 55 years of age is an indication to start antiretroviral therapy (ART), regardless of CD4 status. However, no references to the preferred combination ART (cART) for these patients have been described. Our study compares emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) versus other nucleoside reverse transcriptase inhibitor (NNRTI) regimens in HIV ART-naïve patients who are ≥50 years.
710			_9625 _aInstituto de Investigación imas12
710			_9353 _aServicio de Cirugía Cardiovascular
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/3/pc3221.pdf _ySolicitar documento
942			_n0 _2ddc _cART